MRX-2843, a dual MERTK/FLT3 inhibitor enabled by the NCI Chemical Biology Consortium (CBC) entering Phase 1 clinical trials

Xiaodong Wang

Deborah Deryckere

Doug Graham

H. Shelton Earp

Stephen Frye

0 views
0 downloads

Powered byMorressier logo black

Discover more research and events on morressier.com